Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

Cognitive ADHD Videogame Exploratory Study
A Study to Assess the Feasibility of EVO Gameplay to Engage Children With Attention Deficit Hyperactivity Disorder (ADHD) and to Evaluate Cognitive Interference in Children Ages 8 to 12 Years Old With ADHD Compared to Neuro-typical Children
Status: Enrolling
Updated:  11/14/2017
Duke University
mi
from
Durham, NC
Cognitive ADHD Videogame Exploratory Study
A Study to Assess the Feasibility of EVO Gameplay to Engage Children With Attention Deficit Hyperactivity Disorder (ADHD) and to Evaluate Cognitive Interference in Children Ages 8 to 12 Years Old With ADHD Compared to Neuro-typical Children
Status: Enrolling
Updated: 11/14/2017
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Screening Brief Intervention Referral to Treatment (SBIRT) in New Mexico
SBIRT in New Mexico
Status: Enrolling
Updated:  11/15/2017
Friends Research Institute
mi
from
Baltimore, MD
Screening Brief Intervention Referral to Treatment (SBIRT) in New Mexico
SBIRT in New Mexico
Status: Enrolling
Updated: 11/15/2017
Friends Research Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Telehealth Coaching for Families of Children With Autism
Telehealth Coaching for Families of Children With Autism
Status: Enrolling
Updated:  11/15/2017
Occupational Therapy Education
mi
from
Kansas City, KA
Telehealth Coaching for Families of Children With Autism
Telehealth Coaching for Families of Children With Autism
Status: Enrolling
Updated: 11/15/2017
Occupational Therapy Education
mi
from
Kansas City, KA
Click here to add this to my saved trials
Home-Based Mental Health Evaluation (HOME): A Multi-Site Trial
Home-Based Mental Health Evaluation (HOME): A Multi-Site Trial
Status: Enrolling
Updated:  11/15/2017
VA Portland Health Care System
mi
from
Portland, OR
Home-Based Mental Health Evaluation (HOME): A Multi-Site Trial
Home-Based Mental Health Evaluation (HOME): A Multi-Site Trial
Status: Enrolling
Updated: 11/15/2017
VA Portland Health Care System
mi
from
Portland, OR
Click here to add this to my saved trials
Home-Based Mental Health Evaluation (HOME): A Multi-Site Trial
Home-Based Mental Health Evaluation (HOME): A Multi-Site Trial
Status: Enrolling
Updated:  11/15/2017
Philadelphia VA Medical Center
mi
from
Philadelphia, PA
Home-Based Mental Health Evaluation (HOME): A Multi-Site Trial
Home-Based Mental Health Evaluation (HOME): A Multi-Site Trial
Status: Enrolling
Updated: 11/15/2017
Philadelphia VA Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Home-Based Mental Health Evaluation (HOME): A Multi-Site Trial
Home-Based Mental Health Evaluation (HOME): A Multi-Site Trial
Status: Enrolling
Updated:  11/15/2017
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Home-Based Mental Health Evaluation (HOME): A Multi-Site Trial
Home-Based Mental Health Evaluation (HOME): A Multi-Site Trial
Status: Enrolling
Updated: 11/15/2017
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Escondido, CA
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Escondido, CA
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
San Diego, CA
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Miami, FL
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Orlando, FL
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Atlanta, GA
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Oak Park, IL
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Oak Park, IL
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Lake Charles, LA
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Lake Charles, LA
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Baltimore, MD
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Flowood, MS
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Flowood, MS
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Dayton, OH
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Mason, OH
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Mason, OH
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Austin, TX
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Dallas, TX
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Desoto, TX
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Desoto, TX
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Orem, UT
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Orem, UT
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Clovis, CA
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Clovis, CA
Click here to add this to my saved trials
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Trauma Survivors Outcomes and Support Study IV
Integrating Information Technology Advancements Into Early PTSD Interventions
Status: Enrolling
Updated:  11/17/2017
Harborview Medical Center
mi
from
Seattle, WA
Trauma Survivors Outcomes and Support Study IV
Integrating Information Technology Advancements Into Early PTSD Interventions
Status: Enrolling
Updated: 11/17/2017
Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Acute and Chronic Nicotine Modulation of Reinforcement Learning
Acute and Chronic Nicotine Modulation of Reinforcement Learning
Status: Enrolling
Updated:  11/17/2017
Duke University
mi
from
Durham, NC
Acute and Chronic Nicotine Modulation of Reinforcement Learning
Acute and Chronic Nicotine Modulation of Reinforcement Learning
Status: Enrolling
Updated: 11/17/2017
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
A Comparative Effectiveness Trial of Optimal Patient-Centered Care
A Comparative Effectiveness Trial of Optimal Patient-Centered Care for US Trauma Care Systems
Status: Enrolling
Updated:  11/17/2017
Harborview Medical Center
mi
from
Seattle, WA
A Comparative Effectiveness Trial of Optimal Patient-Centered Care
A Comparative Effectiveness Trial of Optimal Patient-Centered Care for US Trauma Care Systems
Status: Enrolling
Updated: 11/17/2017
Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
Effects of Chemotherapy on Brain Structure and Function
Status: Enrolling
Updated:  11/21/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
Effects of Chemotherapy on Brain Structure and Function
Status: Enrolling
Updated: 11/21/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Brain Function and Structure in Cocaine Dependence
Brain Function and Structure in Cocaine Dependence
Status: Enrolling
Updated:  11/21/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Brain Function and Structure in Cocaine Dependence
Brain Function and Structure in Cocaine Dependence
Status: Enrolling
Updated: 11/21/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Status: Enrolling
Updated:  11/21/2017
Skid Row Housing Trust
mi
from
Los Angeles, CA
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Status: Enrolling
Updated: 11/21/2017
Skid Row Housing Trust
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Status: Enrolling
Updated:  11/21/2017
RAND Corporation
mi
from
Santa Monica, CA
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Enhancing Housing First Programs With a Social Network Substance Use Intervention
Status: Enrolling
Updated: 11/21/2017
RAND Corporation
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo
Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo
Status: Enrolling
Updated:  11/21/2017
Yale School of Medicine
mi
from
New Haven, CT
Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo
Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo
Status: Enrolling
Updated: 11/21/2017
Yale School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)
Cognitive-Behavioral Therapy and Pharmacotherapy Augmentation for Generalized Anxiety Disorder: A Pilot Investigation
Status: Enrolling
Updated:  11/21/2017
Anxiety Disorders Clinic, New York State Psychiatric Institute
mi
from
New York, NY
Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)
Cognitive-Behavioral Therapy and Pharmacotherapy Augmentation for Generalized Anxiety Disorder: A Pilot Investigation
Status: Enrolling
Updated: 11/21/2017
Anxiety Disorders Clinic, New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
Touchstone innovare
mi
from
Grand Rapids, MI
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
Touchstone innovare
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
Community Council of Nashua
mi
from
Nashua, NH
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
Community Council of Nashua
mi
from
Nashua, NH
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
University of Alabama Psychology Clinic
mi
from
Birmingham, AL
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
University of Alabama Psychology Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
Centerstone Research Institute
mi
from
Bloomington, IN
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
Centerstone Research Institute
mi
from
Bloomington, IN
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
Massachusetts Mental Health Center
mi
from
Boston, MA
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
Massachusetts Mental Health Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
University of Minnesota Psychological Clinic
mi
from
Minneapolis, MN
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Psychological Clinic
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
West Central Behavioral Health
mi
from
Claremont, NH
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
West Central Behavioral Health
mi
from
Claremont, NH
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
Riverbend Community Mental Health Center
mi
from
Concord, NH
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
Riverbend Community Mental Health Center
mi
from
Concord, NH
Click here to add this to my saved trials
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated:  11/27/2017
Mental Health Center of Greater Manchester
mi
from
Manchester, NH
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Status: Enrolling
Updated: 11/27/2017
Mental Health Center of Greater Manchester
mi
from
Manchester, NH
Click here to add this to my saved trials
Effect of Galantamine on Smoking Abstinence
The Effect of the Acetylcholinesterase Inhibitor, Galantamine, on Short-term Abstinence
Status: Enrolling
Updated:  11/27/2017
Center for Interdisciplinary Research on Nicotine Addiction, School of Medicine, University of Pennsylvania
mi
from
Philadelphia, PA
Effect of Galantamine on Smoking Abstinence
The Effect of the Acetylcholinesterase Inhibitor, Galantamine, on Short-term Abstinence
Status: Enrolling
Updated: 11/27/2017
Center for Interdisciplinary Research on Nicotine Addiction, School of Medicine, University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
HIV/STI Prevention Among Black Adolescents With Mental Illnesses (Project GOLD)
HIV/STI Prevention Among Black Adolescents With Mental Illnesses
Status: Enrolling
Updated:  11/27/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
HIV/STI Prevention Among Black Adolescents With Mental Illnesses (Project GOLD)
HIV/STI Prevention Among Black Adolescents With Mental Illnesses
Status: Enrolling
Updated: 11/27/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder
Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder
Status: Enrolling
Updated:  11/28/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder
Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder
Status: Enrolling
Updated: 11/28/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rocking Motion: Physiologic Effect on the Surgical Stress Response
Rocking Motion: Physiologic Effect on the Surgical Stress Response
Status: Enrolling
Updated:  11/28/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Rocking Motion: Physiologic Effect on the Surgical Stress Response
Rocking Motion: Physiologic Effect on the Surgical Stress Response
Status: Enrolling
Updated: 11/28/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse
Pharmacogenetic Trial of Noradrenergic Medication for Treatment of Cocaine Abuse
Status: Enrolling
Updated:  11/28/2017
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse
Pharmacogenetic Trial of Noradrenergic Medication for Treatment of Cocaine Abuse
Status: Enrolling
Updated: 11/28/2017
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
Click here to add this to my saved trials
Adolescent Mental Health InSciEd Out
Adolescent Outcomes in Mental Health InSciEd Out
Status: Enrolling
Updated:  11/28/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Adolescent Mental Health InSciEd Out
Adolescent Outcomes in Mental Health InSciEd Out
Status: Enrolling
Updated: 11/28/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Employment-Based Depot Naltrexone Clinical Trial
Employment-Based Depot Naltrexone Clinical Trial
Status: Enrolling
Updated:  11/29/2017
The Center for Learning and Health
mi
from
Baltimore, MD
Employment-Based Depot Naltrexone Clinical Trial
Employment-Based Depot Naltrexone Clinical Trial
Status: Enrolling
Updated: 11/29/2017
The Center for Learning and Health
mi
from
Baltimore, MD
Click here to add this to my saved trials